The headline trial results will be closely monitored by pharmaceutical industry experts. Shares in Novo Nordisk, which ...
Viking says an early-stage study of its obesity pill VK2735 showed adults on the highest dosage lost 8.2% of their body ...
Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...
In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...
AstraZeneca said on Monday its experimental weight-loss pill, licensed a year ago from China's Eccogene for up to $2 billion, ...
It also has another pill, amycretin ... said it expects CagriSema and amycretin to achieve better weight loss results than Wegovy. Lilly is also developing the GIP/GLP-1/glucagon receptor ...
Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...
AstraZeneca (AZN) said Monday at the ObesityWeek conference in San Antonio, Texas that its experimental obesity pill was well-tolerated by ...
Jefferies analyst Roger Song in an investor note said that Viking Therapeutics’ readout for its investigational therapy ...
Apart from its pill, Viking is developing a weight loss injection and other treatments ... injectable treatments from Novo Nordisk and Eli Lilly. Patients with diabetes lost 5.8% of their ...